Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market to Surpass US$20,450.6 Million by 2030

SEATTLE, June 22, 2022 /PRNewswire/ — According to Consistent market informationthe Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is estimated at $10,263.5 million in 2022 and should present a CAGR of 9.0% over the forecast period (2022-2030).

Coherent_Market_Insights_Logo

Key Trends and Analysis of the Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market:

Key market trends include widespread occurrence of Acute Bacterial Skin and Skin Structure Infections (ABSSSI); growing approval of new drugs for acute bacterial infections of the skin and cutaneous appendages (ABSSSI), and increase collaborations, acquisitions and partnerships between key players. These key trends are expected to contribute to the growth of the global acute bacterial skin and skin structure infections (ABSSSI) market.

According to an article published in the journal PLOS One, an open-access peer-reviewed scientific journal in July 2020the lifetime prevalence of skin and soft tissue infections (SSTI), a type of ABSSSI in people who inject drugs (PWID) in London was 64% (abscess and/or cellulitis), based on data collected between October 2017 and March 2019.

In addition, rapid research and development in the field of acute bacterial skin and appendix infections (ABSSSI) for development of a new treatment for the same is expected to fuel the growth of the market over the forecast period. For example, in January 2022Paladin Labs Inc., a subsidiary of Endo International plc, launched Xydalba (dalbavancin for injection), in Canada. Xydalba is a 30-minute intravenous (IV) therapy, which can be given in one or two doses for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.

Further, key players operating in the global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market are focused on adopting inorganic growth strategies such as partnerships, acquisitions, collaborations, and others in order to expand their presence in the global market. For example, in May 2020Advanz Pharma, a UK-based pharmaceutical company, announced that it has completed the acquisition of Correvio Pharma Corp., a Canadaspecialty pharmaceutical company whose product portfolio includes in-licensed drugs such as XYDALBA (dalbavancin hydrochloride) indicated for the treatment of acute bacterial infections of the skin and skin structures (ABSSSI) in adults.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1531

Main market takeaways:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market is expected to show a CAGR of 9.0% during the forecast period, owing to the growing focus of market players on regulatory approvals for novel therapies for Acute Bacterial Skin and Skin Structure Infections (ABSSSI ). For example, in July 2021AbbVie Inc., a United States-based pharmaceutical company announced that it has received United States Food and Drug Administration (USFDA) approval for its drug Dalvance (dalbavancin), administered by intravenous (IV) infusion for the treatment of pediatric patients with ABSSI caused by methicillin resistance Staphylococcus aureus (MRSA) and other gram-positive bacteria.

Among infection types, the community-acquired ABSSSI segment is expected to account for the largest market share in 2022, owing to the increase in drug launches by market players for the treatment of acute bacterial skin infections and skin structures (ABSSSI). For example, in February 2021, Paratek Pharmaceuticals, Inc., a US-based pharmaceutical company, announced that it is expanding the market launch of its oral tetracycline-class antibiotic Nuzyra (omadacycline) in the community setting. Nuzyra is indicated for the treatment of adults with acute skin and skin structure infections (ABSSSI).

Major players operating in the global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) market include Merck & Co., Inc., Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals, Inc., Melinta Therapeutics, Inc., Arrevus, Inc., AbbVie, Inc., Aurobindo Pharma Ltd., Amneal Pharmaceuticals LLC, Sun Pharmaceutical Industries Ltd., Accord Healthcare Ltd., Intas Pharmaceuticals Ltd., Fresenius SE & Co. KGaA, Sandoz Inc., Glenmark Pharmaceuticals Ltd and Cadila Healthcare Ltd..

Customization request @ https://www.coherentmarketinsights.com/insight/request-customization/1531

Detailed segmentation:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Drug Type:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Infection Type:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Administration:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Distribution Channel:

Global Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa

Buy this full report now @ https://www.coherentmarketinsights.com/insight/buy-now/1531

Find the related trend report below:

North America and European Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Market, by drug type (oral and parenteral antibiotics (vancomycin, linezolid, clindamycin, ceftaroline, daptomycin, dalbavancin, tedizolid, and others) and topical antibiotics (hydrogen peroxide, fusidic acid, mupirocin, retapamulin, and povidone-iodine)), by type of infection (hospital-acquired ABSSSI and community-acquired ABSSSI), by route of administration (oral, parenteral, and topical), by distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), and by region (North Americaand Europe) – Size, Share, Prospects & Opportunities Analysis, 2020 – 2027

About Us:

Consistent market information is a global market intelligence and advisory organization focused on helping our plethora of clients achieve transformational growth by helping them make critical business decisions. We have our head office at Indiahaving a sales office in the financial capital of the world in the United States and sales advisers in UK and Japan. Our client base includes players from various industries in more than 57 countries around the world. We create value for our clients through our highly reliable and accurate reports. We are also committed to playing a leadership role in providing insight in various post-COVID-19 industries and to continuing to deliver measurable and sustainable results to our clients.

Contact us:
Mr Shah
Senior Client Partner – Business Development
Consistent market information
Call:
WE: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
E-mail: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com
Follow us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg

Quote

Quote

View original content: https://www.prnewswire.com/news-releases/acute-bacterial-skin-and-skin-structure-infections-absssi-market-to-surpass-us-20-450-6-million -by-2030–coherent-market-insights-301573018.html

SOURCE Consistent Market Information

Ida M. Morgan